Cakir, MuratTarakci, BetiAydin, AliBircan, BurakFirat, SemanurSekerci, Gildeniz2026-04-042026-04-0420250014-29991879-0712https://doi.org/10.1016/j.ejphar.2025.177770https://hdl.handle.net/11616/109648Background: Baricitinib (Bar), used in the management of rheumatoid arthritis, is a selective inhibitor of JAK1/ JAK2. Studies have shown that it inhibits the intracellular signaling of many proinflammatory cytokines by suppressing STAT3 activation. Increased expression and activity of JAK1/JAK2 and STAT3 are associated with kidney damage. Here, we examined the effects of the JAK1/JAK2 inhibitor baricitinib (Bar) on kidney damage in a sepsis model created with cecal ligation and puncture (CLP) in rats. Methods: Rats were divided into four groups: control, CLP, CLP + Bar 3 mg kg- 1, and CLP + Bar 10 mg kg- 1. The cecum of animals to which CLP was applied was first ligated distally, then punctured with a needle to allow the fecal content to spread into the abdominal cavity. Two different doses of Bar (3 mg kg- 1, 10 mg kg- 1) were applied to the treatment groups. Biochemical examinations were performed on the sera of animals sacrificed 24 h after CLP, while histopathological and immunohistochemical examinations were performed on kidney tissue. Resultseninfo:eu-repo/semantics/closedAccessSepsisCecal ligation and punctureBaricitinibJAK1/JAK2Article10024044158810.1016/j.ejphar.2025.1777702-s2.0-105007155038Q1WOS:001506726200001Q10000-0002-9550-91110000-0002-2066-829X0009-0008-8586-3433